The USA's Resolvyx Pharmaceuticals, a Bedford, Massachusetts-headquartered, privately-held biopharmaceutical company, has entered an agreement with the National Neurovision Research Institute to explore novel resolvin therapeutics for eye diseases of the retina that lack current treatments, specifically genetic retinal degenerative diseases and dry age-related macular degeneration.
Under the accord, the NNRI, a recently-established non-profit support organization of the Foundation Fighting Blindness, will fully fund preclinical studies and provide access to specialized research facilities and ocular research experts to evaluate the effectiveness of the new class of drugs, including RX-10001, RX-10008, and RX-20001. Resolvyx will retain all rights to develop and commercialize these compounds and any discoveries that result from the collaboration.
"We are extremely encouraged by the potential for resolvins to treat a number of serious eye diseases, as we have demonstrated that resolvins have a unique ability to naturally inhibit key inflammatory processes, preserve the integrity of eye tissue and promote eye tissue repair," said Per Gjorstrup, chief medical officer of Resolvyx.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze